Lyrica, Pfizer, and how big pharma gets what it wants

23 March 2019 - In 2011, few had heard of Pfizer’s nerve-pain pill Lyrica. It was mostly confined to specialist ...

Read more →

Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says

21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...

Read more →

Biosimilar uptake drivers

5 February 2019 - Information about Government initiatives to encourage the use of biosimilars is now available on the PBS website.  ...

Read more →

Europe closer to biosimilar rule change, despite fierce resistance from pharma

18 January 2019 - EFPIA says it weakens IP commitment - supporters say it will boost exports. ...

Read more →

Canadian payer reports a successful switch to biosimilars

21 January 2019 - In 2018, Green Shield Canada launched its pilot Biosimilar Transition Program, through 3 plan sponsors, under which ...

Read more →

Samsung faces resistance from big pharma in the U.S.

11 January 2019 - Incumbent biologic drug makers use rebates and exclusive contracts to fend off competition from new entrants. ...

Read more →

Underuse of innovative medicines in Germany: A justification for government intervention?

6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse.  ...

Read more →

Novartis joins call asking FDA to stop biosimilar trash-talkers

17 November 2018 - Novartis has joined Pfizer in asking FDA to stop campaigns from branded drugmakers that the pharmas ...

Read more →

German health minister calls for faster adoption of biosimilar drugs

14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...

Read more →

Report on the collection of under co-payment data 2017-18

5 November 2018 - The report on the collection of under co-payment data 2017-18 is now available. ...

Read more →

Drug Utilisation Sub-Committee outcome statement - September 2018

2 November 2018 - The outcome statement from the September 2018 Drug Utilisation Sub Committee meeting is now available. ...

Read more →

Drug Utilisation Sub-Committee utilisation analysis public release documents

26 October 2018 - The utilisation analysis public release documents from the May 2018 DUSC meeting are now available. ...

Read more →

Biosimilar adalimumab: a landmark for NHS medicines optimisation

23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...

Read more →

Improving understanding of biosimilars in the EU

13 September 2018 - New information material made available in several European languages. ...

Read more →

UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis

4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...

Read more →